Coherus Oncology (CHRS) Change in Accured Expenses (2013 - 2026)

Coherus Oncology has reported Change in Accured Expenses for 14 years, with the latest figure at -$7.2 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 13.95% year-over-year to -$7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.0 million (up 87.81% YoY) and the FY2025 annual result came in at -$9.2 million, up 83.83% from the prior year.
• Change in Accured Expenses slipped to -$7.2 million in Q1 2026 per CHRS's latest filing, from $4.4 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $16.5 million in Q3 2023 and troughed at -$55.8 million in Q4 2024.
• A 5-year average of -$4.6 million and a median of -$3.2 million in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses surged 116.73% in 2023, then sank 1223.48% in 2025.
• Over 5 years, Change in Accured Expenses stood at $1.8 million in 2022, then tumbled by 792.96% to -$12.6 million in 2023, then tumbled by 343.22% to -$55.8 million in 2024, then surged by 107.95% to $4.4 million in 2025, then plunged by 261.46% to -$7.2 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$7.2 million, $4.4 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.